Clinical trials of Armodafinil
Cephalon Inc announced about positive outcomes of the clinical trials of the medicine Armodafinil (Nuvigil).
It is a medication for the medical cure of depression in humans, having a bipolar disorder. Bipolar or manicole-depressive symptom complex is described by fluctuations of mood from extraordinary forcible to absolutely decadent spirits. As a rule, patients are depressed during the phase of changes.
During two months research workers compared the efficacy and safety of the drug Armodafinil (150 mg per day) and the placebo as a collateral preparation to stabilizers of mood. 257 patients with a bipolar disorder, who are in the phase of depression, participated in this trial. The progress of patients, taking Generic Armodafinil, was measured on the primary scale with 30 depressive symptoms (IDS-C30). The existence of a mental disorder decreased by a few points (p=0.042).
Leslie Russell reports on the efficaciousness of a new drug and plans to test it in the long period of time. Armodafinil was tolerated very well by patients. Levels of mania, hypomania, dejection and suicidal attempts were compared between the groups of the drug and the placebo. It was noted two major cases of mania among patients with the placebo. Also, they were often exposed to anxiety and hyperactivity.
Generic Armodafinil is the main cure for narcolepsy and sleep apnea.
This preparation is also designed to struggle with daytime drowsiness associated with sleep apnea and for the cure of disturbances of sleep, such as narcolepsy. Nevertheless, the substance wasn’t approved for the cure of a bipolar disorder.
There are some other uses of this drug; in particular it is applied to promote the curtailment of excess weight and for the cure of the chronic fatigue syndrome by athletes to increase energy level and stamina, deficit disorder of attention, depression, Parkinson's disease, schizophrenia, fibromyalgia, cerebral palsy and multiple sclerosis.
Older patients due to ageing can be reduced by the elimination of Generic Armodafinil and its metabolites. Thus, it is necessary to consider the using of lower doses in this group of population. This remedy gives the mark of safety more than in 1100 patients with excessive drowsiness associated with primary disturbance of sleep and vivacity. People, who keep to the right dosing of the drug, don’t have any side effects. It is better to adjust your daily dose with your doctor.
Armodafinil was designed to struggle with daytime drowsiness associated with sleep apnea and for the cure of disturbances of sleep, such as narcolepsy.